3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Suspended
1
Recruiting
1
Enrolling by invitation
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
1045
Lung Neoplasms
803
Small Cell Lung Carcinoma
193
Breast Neoplasms
158
Colorectal Neoplasms
157
Neoplasms
128
Melanoma
116
Ovarian Neoplasms
111
Pancreatic Neoplasms
107
Stomach Neoplasms
95
Neoplasm Metastasis
89
Esophageal Neoplasms
77
Squamous Cell Carcinoma of Head and Neck
75
Prostatic Neoplasms
66
Uterine Cervical Neoplasms
65
Head and Neck Neoplasms
65
Endometrial Neoplasms
61
Triple Negative Breast Neoplasms
59
Colonic Neoplasms
58
Carcinoma, Renal Cell
58
Mesothelioma, Malignant
48
Adenocarcinoma of Lung
48
Urinary Bladder Neoplasms
47
Carcinoma, Hepatocellular
46
Mesothelioma
42
Sarcoma
40
Brain Neoplasms
40
Liver Neoplasms
38
Disease
34
NSCLC
33
Interventions
pembrolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colitis, Ulcerative
×
Thoracic
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled